Tonghua Dongbao Pharmaceutical Management

Management criteria checks 3/4

Tonghua Dongbao Pharmaceutical's CEO is Sheng Leng Chun, appointed in May 2020, has a tenure of 4.08 years. directly owns 0.12% of the company’s shares, worth CN¥19.09M. The average tenure of the management team and the board of directors is 4.1 years and 4.1 years respectively.

Key information

Sheng Leng Chun

Chief executive officer

CN¥3.7m

Total compensation

CEO salary percentage	n/a
CEO tenure	4.1yrs
CEO ownership	0.1%
Management average tenure	4.1yrs
Board average tenure	4.1yrs

Recent management updates

Recent updates

Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Rock Solid Balance Sheet

Jun 19

Improved Earnings Required Before Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Shares Find Their Feet

May 23

CEO

Sheng Leng Chun (50 yo)

4.1yrs

Tenure

CN¥3,728,800

Compensation

Mr. Chun Sheng Leng serves as a Director and General Manager since Mach 27, 2024 and served as the Chairman and General Manager at Tonghua Dongbao Pharmaceutical Co., Ltd. since May 7, 2020 until March 27,...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Sheng Leng Chun	GM & Director	4.1yrs	CN¥3.73m	0.12% CN¥ 19.1m
Junyu Chi	Chief Accountant	4.1yrs	CN¥852.40k	no data
Hong Chen	Chief Engineer & Deputy GM	10.3yrs	CN¥527.20k	0.015% CN¥ 2.4m
Guodong Zhang	Deputy GM & Director	4.1yrs	CN¥1.17m	0.013% CN¥ 2.2m
Wenhai Zhang	Deputy GM & Director	4.1yrs	CN¥1.17m	0.030% CN¥ 5.0m
Zhiqiang Du	Deputy General Manager	2.6yrs	CN¥1.45m	no data
Fan Su	Deputy GM & Board Secretary	4yrs	CN¥992.50k	no data

4.1yrs

Average Tenure

50yo

Average Age

Experienced Management: 600867's management team is considered experienced (4.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Sheng Leng Chun	GM & Director	10.3yrs	CN¥3.73m	0.12% CN¥ 19.1m
Guodong Zhang	Deputy GM & Director	4.1yrs	CN¥1.17m	0.013% CN¥ 2.2m
Wenhai Zhang	Deputy GM & Director	4.1yrs	CN¥1.17m	0.030% CN¥ 5.0m
Junye Wang	Chairman of the Supervisory Board	3.8yrs	CN¥1.17m	0.12% CN¥ 19.2m
Fu Bo Cao	Supervisor	4.1yrs	CN¥173.20k	no data
Wei Wang	Director	3.8yrs	no data	no data
Qingxia He	Employee Representative Supervisor	4.1yrs	no data	no data
Jiahong Li	Chairman of the Board	4.1yrs	CN¥173.20k	no data
Yan Bi	Independent Director	8.9yrs	CN¥100.00k	no data
Dai Xu	Independent Director	2.1yrs	CN¥100.00k	no data
Li Xu	Independent Director	2.1yrs	CN¥100.00k	no data
Jianchun Zhen	Director	less than a year	no data	no data

4.1yrs

Average Tenure

50yo

Average Age

Experienced Board: 600867's board of directors are considered experienced (4.1 years average tenure).

Tonghua Dongbao Pharmaceutical Management

Management criteria checks 3/4

Key information

Recent management updates

Tonghua Dongbao Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Rock Solid Balance Sheet

Price target decreased by 8.4% to CN¥13.15

Improved Earnings Required Before Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Shares Find Their Feet

Consensus EPS estimates increase by 14%

Consensus EPS estimates fall by 16%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Tonghua Dongbao Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released: EPS: CN¥0.59 (vs CN¥0.79 in FY 2022)

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 08, 2024

Price target increased by 7.4% to CN¥14.25

Price target increased by 8.2% to CN¥13.75

Adocia Announces its Partner Tonghua Dongbao Releases Positive Results on the Three Clinical Studies Conducted on BioChaperone Combo THDB0207 Formulation Containing Insulin Glargine and Insulin Lispro from Tonghua Dongbao

Consensus EPS estimates fall by 10%, revenue upgraded

Second quarter 2023 earnings: EPS misses analyst expectations

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Price target increased by 14% to CN¥12.83

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: CN¥0.80 (vs CN¥0.64 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to CN¥11.27

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) commences an Equity Buyback for CNY 360 million worth of its shares, under the authorization approved on March 25, 2022.

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates increase by 15%

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Full year 2021 earnings: EPS exceeds analyst expectations

An unknown buyer signed an agreement to acquire 5% stake in Xiamen Amoytop Biotech Co., Ltd. (SHSE:688278) from Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) for CNY 460 million.

Tonghua Dongbao Pharmaceutical Co., Ltd.(XSSC:600867) dropped from FTSE All-World Index (USD)

Third quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.10 in 3Q 2020)

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) commences an Equity Buyback Plan for 24,000,000 shares, representing 1.18% for CNY 360 million, under the authorization approved on August 25, 2021.

Price target decreased to CN¥13.56

Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.13 in 2Q 2020)

Full year 2020 earnings released: EPS CN¥0.46 (vs CN¥0.40 in FY 2019)

Price target decreased to CN¥14.96

New 90-day low: CN¥11.82

Full year 2020 earnings released: EPS CN¥0.46

Revenue behind estimates

New 90-day low: CN¥12.87

New 90-day low: CN¥13.32

New 90-day high: CN¥14.91

Third quarter earnings released

Third-quarter earnings released: Revenue and earnings miss expectations

Earnings released

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 20, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age